Lv11
40 积分 2024-08-05 加入
Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review
7小时前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
9个月前
已完结
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
9个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
9个月前
已完结
皖公网安备34019202002308
